Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma

Background/Aim: To examine the factors influencing the introduction of the second-line chemotherapy and discuss the selection of first-line agent for hepatocellular carcinoma (HCC). Patients and Methods: We retrospectively studied 154 patients with HCC who received sorafenib therapy. Results: A tota...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-07, Vol.40 (7), p.3953-3960
Main Authors: Moriguchi, Michihisa, Aramaki, Takeshi, Sato, Rui, Iwai, Kenji, Tsuchiya, Satoshi, Asakura, Koiku, Takahashi, Aya, Seko, Yuya, Umemura, Atsushi, Ymaguchi, Kanji, Endo, Masahiro, Itoh, Yoshito
Format: Article
Language:English
Subjects:
Albumins
Bilirubin
Chemotherapy
Hepatocellular carcinoma
Lesions
Liver cancer
Multivariate analysis
Oncology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aim: To examine the factors influencing the introduction of the second-line chemotherapy and discuss the selection of first-line agent for hepatocellular carcinoma (HCC). Patients and Methods: We retrospectively studied 154 patients with HCC who received sorafenib therapy. Results: A total of 109 (70.8%) patients, maintained Child-Pugh grade A and Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1 upon sorafenib discontinuation. Multivariate analysis revealed that the up-to-seven criteria status in the hepatic lesion [p=0.019; odds ratio=OR, 2.685], albumin–bilirubin (ALBI) grade (p=0.002; OR=3.589), and macroscopic vascular invasion (MVI) (p=0.008; OR=2.972) were significant factors at sorafenib initiation that influenced the maintenance of Child-Pugh grade A and ECOG-PS ≤1 upon therapy discontinuation. Conclusion: Not only ALBI grade and MVI, but also up-to-seven criteria status in the hepatic lesion influence the introduction of second-line therapy, and could affect the selection of the first-line therapy.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14387